Armen Yerevanian1,2,3, Alexander A Soukas4,5,6. 1. Department of Medicine, Diabetes Unit, Endocrine Division, and Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, CPZN6224, Boston, MA, 02114, USA. 2. Department of Medicine, Harvard Medical School, Boston, MA, 02114, USA. 3. Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA. 4. Department of Medicine, Diabetes Unit, Endocrine Division, and Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge Street, CPZN6224, Boston, MA, 02114, USA. asoukas@mgh.harvard.edu. 5. Department of Medicine, Harvard Medical School, Boston, MA, 02114, USA. asoukas@mgh.harvard.edu. 6. Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA. asoukas@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Metformin has multiple benefits for health beyond its anti-hyperglycemic properties. The purpose of this manuscript is to review the mechanisms that underlie metformin's effects on obesity. RECENT FINDINGS: Metformin is a first-line therapy for type 2 diabetes. Large cohort studies have shown weight loss benefits associated with metformin therapy. Metabolic consequences were traditionally thought to underlie this effect, including reduction in hepatic gluconeogenesis and reduction in insulin production. Emerging evidence suggests that metformin-associated weight loss is due to modulation of hypothalamic appetite regulatory centers, alteration in the gut microbiome, and reversal of consequences of aging. Metformin is also being explored in the management of obesity's sequelae such as hepatic steatosis, obstructive sleep apnea, and osteoarthritis. Multiple mechanisms underlie the weight loss-inducing and health-promoting effects of metformin. Further exploration of these pathways may be important in identifying new pharmacologic targets for obesity and other aging-associated metabolic diseases.
PURPOSE OF REVIEW: Metformin has multiple benefits for health beyond its anti-hyperglycemic properties. The purpose of this manuscript is to review the mechanisms that underlie metformin's effects on obesity. RECENT FINDINGS:Metformin is a first-line therapy for type 2 diabetes. Large cohort studies have shown weight loss benefits associated with metformin therapy. Metabolic consequences were traditionally thought to underlie this effect, including reduction in hepatic gluconeogenesis and reduction in insulin production. Emerging evidence suggests that metformin-associated weight loss is due to modulation of hypothalamic appetite regulatory centers, alteration in the gut microbiome, and reversal of consequences of aging. Metformin is also being explored in the management of obesity's sequelae such as hepatic steatosis, obstructive sleep apnea, and osteoarthritis. Multiple mechanisms underlie the weight loss-inducing and health-promoting effects of metformin. Further exploration of these pathways may be important in identifying new pharmacologic targets for obesity and other aging-associated metabolic diseases.
Entities:
Keywords:
Aging; Appetite regulation; Metformin; Obesity; Type 2 diabetes; Weight loss
Authors: L X Cubeddu; H Bönisch; M Göthert; G Molderings; K Racké; G Ramadori; K J Miller; H Schwörer Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2000-01 Impact factor: 3.000
Authors: C J Glueck; R N Fontaine; P Wang; M T Subbiah; K Weber; E Illig; P Streicher; L Sieve-Smith; T M Tracy; J E Lang; P McCullough Journal: Metabolism Date: 2001-07 Impact factor: 8.694
Authors: R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman Journal: Diabetes Date: 2000-12 Impact factor: 9.461
Authors: G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Adrian P Merce; Loredana N Ionică; Anca M Bînă; Simona Popescu; Rodica Lighezan; Lucian Petrescu; Claudia Borza; Adrian Sturza; Danina M Muntean; Octavian M Creţu Journal: Mol Cell Biochem Date: 2022-06-20 Impact factor: 3.396
Authors: Jane L Tarry-Adkins; Imogen D Grant; Susan E Ozanne; Rebecca M Reynolds; Catherine E Aiken Journal: Diabetes Ther Date: 2021-06-02 Impact factor: 2.945